Cooperative Huntington's Observational Research Trial
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | April 10, 2006 | ||||
| Last Updated Date | March 4, 2011 | ||||
| Start Date ICMJE | February 2006 | ||||
| Estimated Primary Completion Date | December 2020 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE | Not Provided | ||||
| Original Primary Outcome Measures ICMJE | Not Provided | ||||
| Change History | Complete list of historical versions of study NCT00313495 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Cooperative Huntington's Observational Research Trial | ||||
| Official Title ICMJE | Cooperative Huntington's Observational Research Trial | ||||
| Brief Summary | The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in order to learn more about HD, develop potential treatments for HD, and to plan for future research studies of experimental drugs aimed at slowing or postponing the onset and progression of HD. |
||||
| Detailed Description | COHORT (Cooperative Huntington Observational Research Trial) is a coordinated research effort by Huntington Study Group research centers worldwide to prospectively collect data from consenting individuals who are affected by Huntington's disease (HD) and who are part of an HD family. The systematically accrued data from annual prospective assessments will relate clinical characteristics (phenotypes) between families with genetic and environmental factors. The knowledge from these relationships will better inform us about the onset and progression of HD, help identify potential interventions for HD, and aid in planning research studies of experimental treatments aimed at slowing or postponing the onset of HD. The consented collection of biological samples will further provide research material and correlative data for scientists to identify biomarkers that parallel the development and progression of HD. Identification of biomarkers will in turn contribute to our understanding of HD and enhance the efficiency and power of disease-modifying therapeutic trials. |
||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Time Perspective: Prospective | ||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Retention: Samples With DNA Description: Blood, DNA and Urine |
||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population |
|
||||
| Condition ICMJE | Huntington Disease | ||||
| Intervention ICMJE | Not Provided | ||||
| Study Group/Cohort (s) | Not Provided | ||||
| Publications * | Dorsey ER; Huntington Study Group COHORT Investigators. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One. 2012;7(2):e29522. Epub 2012 Feb 16. | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Recruiting | ||||
| Estimated Enrollment ICMJE | 5000 | ||||
| Estimated Completion Date | December 2020 | ||||
| Estimated Primary Completion Date | December 2020 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | Not Provided | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts ICMJE |
|
||||
| Location Countries ICMJE | United States, Australia, Canada | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00313495 | ||||
| Other Study ID Numbers ICMJE | COHORT | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | Ira Shoulson, MD/Principal Investigator, University of Rochester | ||||
| Study Sponsor ICMJE | HP Therapeutics Foundation | ||||
| Collaborators ICMJE | Huntington Study Group | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | HP Therapeutics Foundation | ||||
| Verification Date | March 2011 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||